7,718.60

-29.11

-0.38%

53,414.25

-271.86

-0.51%

26,506.99

-77.11

-0.29%

2,975.65

+7.38

+0.25%

14.53

+0.21

+1.47%

4,476.60

-63.30

-1.39%

79,625.98

-1,559.30

-1.92%

Crude Oil Oct 26

91.48

+0.18

+0.20%

NasdaqGS - Delayed Quote USD

Biogen Inc. (BIIB)

220.83 -3.68 (-1.64%)

At close: September 4 at 4:00:01 PM EDT

220.99 +0.16 (+0.07%)

After hours: September 4 at 7:33:20 PM EDT

Trade Biogen on Coinbase

Loading Chart for BIIB

Chart Range Bar

Interval:

In partnership with ChartIQ

This Biotech Wins a Big FDA Approval. Why Wall Street Is Shrugging.

This Biotech Wins a Big FDA Approval. Why Wall Street Is Shrugging.

Exelixis (EXEL) Up 13.3% Since Last Earnings Report: Can It Continue?

Exelixis (EXEL) Up 13.3% Since Last Earnings Report: Can It Continue?

Why Is Veeva Systems (VEEV) Winning Big In AI For Biopharma?

Why Is Veeva Systems (VEEV) Winning Big In AI For Biopharma?

Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)

Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)

Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)

Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)

Biogen (BIIB) Brings At Home Weekly Alzheimer’s Injection To U.S. Patients

Biogen (BIIB) Brings At Home Weekly Alzheimer’s Injection To U.S. Patients

Biogen (BIIB) Stock Could Be 48% Below Fair Value On New Dravet Data

Biogen (BIIB) Stock Could Be 48% Below Fair Value On New Dravet Data

LEQEMBI® (lecanemab) Subcutaneous Formulation as an Initiation Treatment for Early Alzheimer’s Disease Approved in China

LEQEMBI® (lecanemab) Subcutaneous Formulation as an Initiation Treatment for Early Alzheimer’s Disease Approved in China

Biogen’s (BIIB) Immunology Bet Meets A Pricier Balance Sheet

Biogen’s (BIIB) Immunology Bet Meets A Pricier Balance Sheet

Why Is Vertex (VRTX) Up 14.4% Since Last Earnings Report?

Why Is Vertex (VRTX) Up 14.4% Since Last Earnings Report?

Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)

Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)

AMGN

GILD

BMY

AZN

GSK

SNY

NVS

MRK

ABBV

RHHBY

Mobilize your Website

View Site in Mobile | Classic

Share by: